Rochelle Lazarus - Merck Independent Director

MRK Stock  USD 105.38  1.49  1.39%   

  Director

Ms. Rochelle B. Lazarus is Independent Director of the Company since 2004.
Age: 71
Tenure: 19 years
Address: 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Phone: 908 740 4000
Website: https://www.merck.com
Lazarus has extensive expertise in management, including talent management, marketing, and communications, as well as a track record of achievement and sound judgment, as demonstrated by her history as Chairman and CEO of Ogilvy & Mather. Through her role as Trustee of New York Presbyterian Hospital, she has also gained experience in overseeing the management of medical providers, a key stakeholder group of the Company. In addition, her strong background in reputation management and consumer insight provides the Board with valuable insight into the Company’s branding strategy. She also has extensive experience as a director of charitable and civic organizations.

Rochelle Lazarus Latest Insider Activity

Tracking and analyzing the buying and selling activities of Rochelle Lazarus against Merck stock is an integral part of due diligence when investing in Merck. Rochelle Lazarus insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Rochelle Lazarus over six months ago
Blackstone exotic insider transaction detected

Merck Management Efficiency

Merck Company has Return on Asset of 0.1268 % which means that on every $100 spent on asset, it made $0.1268 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 38.1847 %, implying that it generated $38.1847 on every 100 dollars invested. Merck management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Merck Return on Average Assets are increasing as compared to previous years. The last year's value of Return on Average Assets was reported at 11.91. The current Return on Average Equity is estimated to increase to 39.91, while Return on Investment is projected to decrease to 14.23. The current Tax Liabilities is estimated to increase to about 4.8 B, while Total Liabilities is projected to decrease to under 55.7 B.
The company has 30.69 B in debt with debt to equity (D/E) ratio of 0.68, which is OK given its current industry classification. Merck Company has a current ratio of 1.43, which is typical for the industry and considered as normal. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Tom WoiwodeCrispr Therapeutics AG
43
Bruno BaillavoineCEL-SCI Corp
65
Steven RauscherAcorda Therapeutics
64
George ScangosAgilent Technologies
72
Paul ClarkAgilent Technologies
72
Giles KerrAdaptimmune Therapeutics Plc
56
Elliot SigalAdaptimmune Therapeutics Plc
65
Barry GreeneAcorda Therapeutics
54
Sue RatajAgilent Technologies
63
Tal ZaksAdaptimmune Therapeutics Plc
N/A
David MottAdaptimmune Therapeutics Plc
52
Lawrence AllevaAdaptimmune Therapeutics Plc
68
Lorin RandallAcorda Therapeutics
74
Michael HaydenAurinia Pharmaceuticals
66
Peder JensenAcorda Therapeutics
63
John FureyAdaptimmune Therapeutics Plc
53
Charles RowlandAurinia Pharmaceuticals
56
Dow WilsonAgilent Technologies
61
Alexander EsterhazyCEL-SCI Corp
72
Robert WatsonCEL-SCI Corp
61
Ali BehbahaniCrispr Therapeutics AG
40
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people. Merck Company (MRK) is traded on New York Stock Exchange in USA and employs 67,000 people. Merck is listed under Pharmaceuticals category by Fama And French industry classification.

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Caroline Litchfield, Chief Financial Officer, Executive Vice President
Mirian GraddickWeir, Executive Vice President - Human Resources
Jannie Oosthuizen, Lead - Human Health U.S.
Jennifer Mauer, VP Communications
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Michael Klobuchar, Executive Vice President Chief Strategy Officer
Patricia Russo, Independent Director
David Williams, Executive Vice President Chief Information Chief Information and Digital Officer
Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing
Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
William Harrison, Lead Independent Director
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Deepak Khanna, Lead - Human Health International
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Risa LavizzoMourey, Independent Director
Thomas Glocer, Lead Independent Director
Craig Thompson, Independent Director
Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Arpa Garay, Lead - Human Health Global Marketing
Christine Seidman, Independent Director
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories
Stephen Mayo, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Peter Dannenbaum, VP Relations
Clark Golestani, CIO and Executive VP
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer
Robert JD, Pres Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Merck Investors Sentiment

The influence of Merck's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Merck. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Merck's public news can be used to forecast risks associated with investment in Merck. The trend in average sentiment can be used to explain how an investor holding Merck can time the market purely based on public headlines and social activities around Merck Company. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Merck's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Merck's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Merck's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Merck.

Merck Implied Volatility

    
  27.39  
Merck's implied volatility exposes the market's sentiment of Merck Company stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Merck's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Merck stock will not fluctuate a lot when Merck's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Merck Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.29) 
Market Capitalization
275.3 B
Quarterly Revenue Growth
0.137
Return On Assets
0.1268
Return On Equity
38.1847
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.